Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) has been given an average rating of “Buy” by the six research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $34.75.
Several brokerages have recently commented on IMGO. HC Wainwright decreased their target price on Imago BioSciences from $37.00 to $36.00 and set a “buy” rating for the company in a research report on Friday, March 25th. Zacks Investment Research raised Imago BioSciences from a “sell” rating to a “hold” rating in a report on Friday, February 11th.
In other news, insider Jennifer Peppe sold 13,000 shares of Imago BioSciences stock in a transaction on Monday, February 7th. The stock was sold at an average price of $20.48, for a total transaction of $266,240.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Laura G. Eichorn sold 8,000 shares of Imago BioSciences stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $21.60, for a total value of $172,800.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,000 shares of company stock worth $827,960.
Shares of NASDAQ IMGO opened at $16.35 on Friday. Imago BioSciences has a fifty-two week low of $14.61 and a fifty-two week high of $35.68. The business has a 50 day moving average price of $20.14 and a two-hundred day moving average price of $21.42.
Imago BioSciences (NASDAQ:IMGO – Get Rating) last issued its earnings results on Thursday, March 24th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.06). Equities analysts expect that Imago BioSciences will post -1.76 earnings per share for the current fiscal year.
About Imago BioSciences (Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.